Secondary Stock Offerings
By The Online Investor Staff, updated Thu., Mar. 28, 8:32 AM
Slide #23. Cognition Therapeutics, Inc. — Secondary Offering
Company: |
Cognition Therapeutics, Inc. (NASDAQ:CGTX) |
Date announced: |
3/11/2024 |
Shares Offered: |
6,571,428 |
Date of Pricing: |
3/11/2024 |
Price Per Share: |
$1.75 |
Secondary Offering Details: |
Cognition Therapeutics, Inc. ("Cognition," the "Company" or "We") (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock. Cognition also intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock to be sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock to be sold in the proposed offering will be sold by Cognition. -updated 3/11- Cognition Therapeutics, Inc. ("Cognition," the "Company" or "We") (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock. Cognition has also granted the underwriters a 30-day option to purchase up to 985,714 additional shares of its common stock sold in the offering on the same terms and conditions. The Company expects to close the offering on March 14, 2024, subject to the satisfaction of customary closing conditions. |
Cognition Therapeutics is a clinical-stage biopharmaceutical company. Co. is developing a pipeline of small molecule product candidates that are designed to target the o-2 (sigma-2) receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer's disease, dry Age-Related Macular Degeneration (AMD), geographic atrophy (a form of dry AMD), and other conditions. Co.'s main product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Co. is initially focused on the development of CT1812 for the treatment of AD by targeting the accumulation of B-amyloid.
Open the CGTX Page at The Online Investor »
Company Name: |
Cognition Therapeutics Inc |
Website: |
www.cogrx.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding CGTX: |
3 |
Total Market Value Held by ETFs: |
$1.71M |
Total Market Capitalization: |
$55.00M |
% of Market Cap. Held by ETFs: |
3.11% |
|
Open the CGTX Page at The Online Investor (in a new window) »
|
March 28, 2024 8:32 AM Eastern
Strong Buy (4.00 out of 4)
95th percentile
|
|